Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Plakoglobin (JUP) is a cytoplasmic protein found in both desmosomes and adherens junctions, serving as a critical component for "cell-cell adhesion" in cardiac muscle and epithelial tissues[1][3]. As a member of the catenin family, it anchors cadherins to the cytoskeleton and maintains tissue integrity[1][2]. JUP plays dynamic roles in regulating intercellular adhesion, tissue architecture, and multiple signaling pathways, such as Wnt/β-catenin and p53, with implications in both normal development and disease. Mutations or dysregulation of plakoglobin are linked to arrhythmogenic right ventricular dysplasia and several cancers. JUP functions as a potential diagnostic and prognostic biomarker and is being considered as a possible therapeutic target, particularly in oncology[2][3].
Not established for therapeutics; described mechanisms include potential modulation of signaling pathways (e.g., Wnt/β-catenin, p53, cadherin-mediated signaling) if hypothetical drugs target expression or function[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Plakoglobin (JUP).